Unia Europejska - islandzki - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - skjaldkirtilshormón - hypoparateyroidism - kalsíumsterastasis - natpar er ætlað sem viðbótarmeðferð hjá fullorðnum sjúklingum með langvarandi ofsabjúgshjúp, sem ekki er hægt að stjórna með nægilegum hætti með venjulegri meðferð einu sér.

Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - escitalopramum oxalat - filmuhúðuð tafla - 5 mg

Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - escitalopramum oxalat - filmuhúðuð tafla - 10 mg

Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - escitalopramum oxalat - filmuhúðuð tafla - 15 mg

Unia Europejska - islandzki - EMA (European Medicines Agency)

mylan pharmaceuticals limited - duloxetin - neuralgia; diabetic neuropathies; depressive disorder, major; anxiety disorders - psychoanaleptics, - meðferð helstu þunglyndi;meðferð sykursýki útlæga taugaverkir;meðferð almenn kvíða;duloxetine mylan er ætlað í fullorðnir.

Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - venlafaxinum hýdróklóríð - hart forðahylki - 150 mg

Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - venlafaxinum hýdróklóríð - hart forðahylki - 75 mg

Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - venlafaxinum hýdróklóríð - hart forðahylki - 37,5 mg

Unia Europejska - islandzki - EMA (European Medicines Agency)

esteve pharmaceuticals, s.a. - duloxetin - anxiety disorders; depressive disorder, major; diabetic neuropathies - psychoanaleptics, - meðferð helstu þunglyndi;meðferð sykursýki útlæga taugaverkir;meðferð almenn kvíða;xeristar er ætlað í fullorðnir.

Unia Europejska - islandzki - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.